SILICON VALLEY, CA — August 14, 2025 — Leads & Copy — ABVC BioPharma, Inc. (NASDAQ: ABVC) announced its financial results for the second quarter ended June 30, 2025, highlighting strategic initiatives aimed at stabilizing operations and strengthening its balance sheet.
The company reported a 103% increase in total consolidated assets, reaching $16.2 million, and shareholders’ equity rose to $9.5 million. ABVC’s diluted loss per share improved to $(0.13) for Q2 2025. Following the close of Q2, ABVC acquired farmland in Taiwan for $3.3 million to support R&D and GMP expansion. In July 2025, the company received $350,000 in licensing revenue.
Dr. Uttam Patil, ABVC’s CEO, stated that the results reflect the strategic discipline applied across the business, positioning ABVC for sustainable long-term growth.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device under development.
Uttam Patil, Email: uttam@ambrivis.com, 4928-4786-9789
Source: ABVC BioPharma
